argenx SE American Depositary Receipt (ARGX)
NASDAQ
Closed
Oct 6, 2026
Day's Range
909.9552 wk Range
661.85Overview - ARGX - argenx SE American Depositary Receipt
Key Statistics
Valuation
Enterprise Value
1.43T
P/E (Trailing)
‪34.96‬
P/E (Forward)
‪26.47‬
PEG Ratio
‪26.47‬
Price / Sales (TTM)
‪10.75‬
Price / Book
‪170.74‬
EV / EBITDA
‪887.84‬
Profitability
Gross Margin
‪90.42%‬
Profit Margin
‪32.26%‬
Operating Margin
‪31.99%‬
Return on Assets
‪11.63%‬
Return on Equity
‪23.63%‬
Ownership
Shares Outstanding
62.53M
Float
1.56B
Short % of Shares Outstanding
‪2.10%‬
Held by Insiders
‪0.00%‬
Held by Institutions
‪46.06%‬
Price stats
Beta
‪-0.02‬
50-Day Avg
‪956.72‬
200-Day Avg
‪851.23‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
11 analysts
Average price target
‪$ 1,175.61‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ARGX - argenx SE American Depositary Receipt
Peers - ARGX - argenx SE American Depositary Receipt
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
- AXSMNASDAQAxsome Therapeutics Inc.9.37BMarket Cap+33.09%52-week change-48.69P/E (Trailing)‪-24.67%‬Profit Margin
Profile Summary - ARGX - argenx SE American Depositary Receipt
About
argenx SE American Depositary Receipt is an American depositary receipt representing shares of argenx SE, a Netherlands-based biopharmaceutical company focused on developing and commercializing antibody-based therapies for severe autoimmune and neuromuscular diseases. The company’s current portfolio centers on…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
